AIDS Wasting in Women: Anabolic Effects of Testosterone
AIDS Wasting Syndrome
About this trial
This is an interventional treatment trial for AIDS Wasting Syndrome focused on measuring AIDS, HIV, weight loss, Wasting Syndrome, testosterone, androgen levels, hormones
Eligibility Criteria
Inclusion Criteria: Females using acceptable form of birth control during study, including barrier contraception or IUD but excluding oral contraceptives or Depo-Provera Documented HIV infection Free testosterone level 3.0 pg/mL Weight < 90% or weight loss > 10% of pre-illness weight Exclusion Criteria: Pregnant or actively seeking pregnancy Breast feeding New opportunistic infection diagnosed within 4 weeks of the study Requiring parenteral nutrition or pharmacologic glucocorticoid therapy Intractable diarrhea (6 stools/day) Androgen, estrogen, progestational derivative, or glucocorticoid administration within 3 months of the study, including Megace New retroviral therapy within 6 weeks of study SGOT > 5 X normal and/or clinically significant liver disease Creatinine > 2.0 mg/dL and/or clinically significant renal disease Hgb < 8.0 g/dL Active substance abuse or alcoholism
Sites / Locations
- Massachusetts General Hospital